Abstract:ID 54817 Poster Board 319 Objective: Globally, cancer is a major burden of disease threatening human health. To date, immune checkpoint inhibitors are monoclonal antibodies that cover various cancer indications as monotherapy or in combination, have revealed remarkable clinical success in a wide range of solid tumors and hematologic malignancies. Due to the inherent limitations of antibodies, it is reasonable to consider discovering orally bioavailable small molecule inhibitors that target programmed cell death protein 1/programmable death-ligand 1 (PD-1/PD-L1) signaling pathway as alternative. The aim of this study is to mainly focus on computer aided drug design (CADD) process to predict the possible small molecules that can interact with PD-1, and further serve as starting points to design potential safe and efficacious compounds in cancer treatment. Methods: Possible ligand binding sites on the PD-1 protein were initially predicted by DoGSiteScorer, FTsite and PrankWeb servers. The 6 highest-ranked clusters based on the "druggability" score from PocketQuery were selected as queries for pharmacophore-based virtual screening using ZincPharmer. Drug likeness property assessment and ADME-tox prediction have been performed by using SwissADME and ADMETlab. Results: 30 hit compounds were initially retrieved by pharmacophore-based virtual screening. Thereafter, 5 compounds with lowest Gibb's free energy (G) values, namely ZINC85867378, ZINC16267039, ZINC64219346, ZINC68604154 and ZINC20576138, have been chosen for further evaluation. ZINC68604154 showed G of -9.07 kcal/mol and appeared to have reasonable oral bioavailability, low drug-drug interaction potential, and low toxicity risk. Conclusion: This study establishes the workflow combining pharmacophore virtual screening, molecular docking, and absorption, distribution, metabolism, excretion - toxicity (ADMET) prediction to identify possible small molecules that can interact with PD-1. The identified compounds might serve as starting points to design potential safe and efficacious molecules in cancer Immunotherapy. Further evaluation through in vitro and in vivo is necessary to optimize drug properties.

In vitro assay for the development of small molecule inhibitors targeting PD-1/PD-L1

Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway

Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway

Research progress of anti-PD-1 / PD-L1 immunotherapy biomarkers

Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles

Computational Approach for the Development of pH-Selective PD-1/PD-L1 Signaling Pathway Inhibition in Fight with Cancer

In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction

Progress on the Study of PD-L1 Detection Methods in Non-small Cell Lung Cancer

Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation

Design, synthesis, pharmacological evaluation, and computational study of benzo[d] isothiazol-based small molecule inhibitors targeting PD-1/PD-l1 interaction

Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy

Further investigation of blockade effects and binding affinities of selected natural compounds to immune checkpoint PD-1/PD-L1

Computational Investigations on the Natural Small Molecule as an Inhibitor of Programmed Death Ligand 1 for Cancer Immunotherapy

Design, Synthesis and Biological Evaluation of Biphenyl-1,2,3-Triazole Hybrid Analogues as PD-1/PD-L1 Inhibitors

Discovery of Novel PD-L1 Small-Molecular Inhibitors with Potent In Vivo Anti-tumor Immune Activity

A Computational Approach to Identify Small Molecules Interact with Crystal Structure of Programmed Cell Death Protein 1 as Potential Therapeutics for Cancer Immunotherapy

Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking, ADMET, and Molecular Dynamics (MD) Simulation of Potential Inhibitors of PD-L1 from the Library of Marine Natural Products

Strategies for developing PD-1 inhibitors and future directions

Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy

Rational Development of Molecularly Imprinted Nanoparticles for Blocking PD-1/PD-L1 Axis

Small molecule and PROTAC molecule experiments in vitro and in vivo, focusing on mouse PD-L1 and human PD-L1 differences as targets